0000000000450272

AUTHOR

Roberto Nisini

showing 2 related works from this author

Janus -faced liposomes enhance antimicrobial innate immune response in Mycobacterium tuberculosis infection

2012

We have generated unique asymmetric liposomes with phosphatidylserine (PS) distributed at the outer membrane surface to resemble apoptotic bodies and phosphatidic acid (PA) at the inner layer as a strategy to enhance innate antimycobacterial activity in phagocytes while limiting the inflammatory response. Results show that these apoptotic body-like liposomes carrying PA (ABL/PA) ( i ) are more efficiently internalized by human macrophages than by nonprofessional phagocytes, ( ii ) induce cytosolic Ca 2+ influx, ( iii ) promote Ca 2+ -dependent maturation of phagolysosomes containing Mycobacterium tuberculosis (MTB), ( iv ) induce Ca 2+ -dependent reactive oxygen species (ROS) production, (…

MaleAntitubercular AgentsApoptosisSettore MED/07Mice0302 clinical medicineInnateInbred BALB CMycobacterium tuberculosis liposomes0303 health sciencesMice Inbred BALB CMultidisciplinaryLeukemiaTumorbiologyMacrophages; Leukemia Monocytic Acute; Animals; Apoptosis; Calcium; Humans; Disease Models Animal; Mice; Cell Line Tumor; Immunity Innate; Reactive Oxygen Species; Mice Inbred BALB C; Liposomes; Phosphatidylserines; Tuberculosis Pulmonary; Adult; Bronchoalveolar Lavage Fluid; Middle Aged; Antitubercular Agents; Phagocytosis; Male; Mycobacterium tuberculosis; IsoniazidInterleukinPulmonaryMiddle AgedSettore BIO/193. Good healthPNAS PlusLeukemia Monocytic AcuteTumor necrosis factor alphaBronchoalveolar Lavage FluidIntracellularAdultPhagocytosisPhosphatidylserinesAcutePhagolysosomeSettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICAMicrobiologyCell LineMycobacterium tuberculosis03 medical and health sciencesPhagocytosisCell Line TumorIsoniazidTuberculosisAnimalsHumansTuberculosis Pulmonary030304 developmental biologySettore MED/04 - Patologia GeneraletherapyInnate immune systemMonocyticAnimalMacrophagesImmunityMycobacterium tuberculosisbiology.organism_classificationImmunity InnateDisease Models AnimalApoptosisImmunologyDisease ModelsLiposomesCalciumReactive Oxygen Species030215 immunology
researchProduct

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development

2017

International audience; TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, …

TuberculosiImmunologybacille Calmette–Guérin610 Medicine & healthReview[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesTuberculosis; Bacille Calmette-Guérin; Vaccination; Biomarker; Clinical trial; Portfolio management; Discovery[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]Immunology and AllergyBacille Calmette-Guérinbacille Calmette-Guérinbacille Calmette-Guerin2403 Immunology10179 Institute of Medical MicrobiologyBacille Calmette-Guérin; Biomarker; Clinical trial; Discovery; Portfolio management; Tuberculosis; Vaccination; Immunology and Allergy; Immunologyclinical trialvaccination[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticstuberculosis2723 Immunology and Allergy570 Life sciences; biologybiomarkerportfolio managementdiscovery
researchProduct